gene,drug,diplotype,implications,recommendation,ref_guide,drug_id,cHGVS,pHGVS,rsid,location,QUAL,depth,readsratio
ABCG2,allopurinol,rs2231142 reference (G)/rs2231142 reference (G),The guideline does not provide a description of the impact of the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ) on allopurinol.,The guideline does not provide a recommendation for allopurinol in patients with the the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ),DPWG Guideline Annotation,PA448320,,,,,,,
ABCG2,rosuvastatin,rs2231142 reference (G)/rs2231142 reference (G),ABCG2: Typical myopathy risk and rosuvastatin exposure;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.,"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt; 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA134308647,,,,,,,
CACNA1S,desflurane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA164749136,,,,,,,
CACNA1S,enflurane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA449461,,,,,,,
CACNA1S,halothane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA449845,,,,,,,
CACNA1S,isoflurane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA450106,,,,,,,
CACNA1S,methoxyflurane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA450434,,,,,,,
CACNA1S,sevoflurane,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA451341,,,,,,,
CACNA1S,succinylcholine,Reference/Reference,"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA451522,,,,,,,
CFTR,ivacaftor,Reference/Reference,CFTR: An individual diagnosed with cystic fibrosis (CF) and negative for a CFTR variant listed in the FDA-approved drug label as being responsive to ivacaftor.,Ivacaftor is not recommended,CPIC Guideline Annotation,PA165950341,,,,,,,
CYP2B6,efavirenz,*1/*1,CYP2B6: Normal efavirenz metabolism,"Initiate efavirenz with standard dosing (600 mg/day)
<h4 id=""other-considerations"">Other Considerations</h4>
The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype (PMID 24522178).",CPIC Guideline Annotation,PA449441,,,,,,,
CYP2B6,sertraline,*1/*1,CYP2B6: Normal metabolism of sertraline to less active compounds.;CYP2C19: Normal metabolism,Initiate therapy with recommended starting dose.,CPIC Guideline Annotation,PA451333,,,,,,,
CYP2C19,amitriptyline,*1/*1,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA448385,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,citalopram,*1/*1,CYP2C19: Normal metabolism,Initiate therapy with recommended starting dose,CPIC Guideline Annotation,PA449015,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,clomipramine,*1/*1,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449048,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,clopidogrel,*1/*1,CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity,"If considering clopidogrel, use at standard dose (75 mg/day)
<h4 id=""other-considerations"">Other Considerations</h4>
For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.",CPIC Guideline Annotation,PA449053,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,dexlansoprazole,*1/*1,CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",CPIC Guideline Annotation,PA166110257,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,doxepin,*1/*1,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449409,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,escitalopram,*1/*1,CYP2C19: Normal metabolism,Initiate therapy with recommended starting dose,CPIC Guideline Annotation,PA10074,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,imipramine,*1/*1,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449969,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,lansoprazole,*1/*1,CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",CPIC Guideline Annotation,PA450180,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,omeprazole,*1/*1,CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",CPIC Guideline Annotation,PA450704,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,pantoprazole,*1/*1,CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",CPIC Guideline Annotation,PA450774,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,sertraline,*1/*1,CYP2B6: Normal metabolism of sertraline to less active compounds.;CYP2C19: Normal metabolism,Initiate therapy with recommended starting dose.,CPIC Guideline Annotation,PA451333,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,trimipramine,*1/*1,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA451791,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C19,voriconazole,*1/*1,CYP2C19: Normal voriconazole metabolism,"Initiate therapy with recommended standard of care dosing
<h4 id=""other-considerations"">Other Considerations</h4>
Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",CPIC Guideline Annotation,PA10233,test,test,rs3758581,chr10:94842866:A>G,1478.06,"0,46",1.0
CYP2C9,celecoxib,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA448871,,,,,,,
CYP2C9,flurbiprofen,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA449683,,,,,,,
CYP2C9,fluvastatin,*1/*1,CYP2C9: Normal exposure.;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.,"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA449688,,,,,,,
CYP2C9,fosphenytoin,*1/*1,CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",CPIC Guideline Annotation,PA164746820,,,,,,,
CYP2C9,ibuprofen,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA449957,,,,,,,
CYP2C9,lornoxicam,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA165958395,,,,,,,
CYP2C9,meloxicam,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA450353,,,,,,,
CYP2C9,phenytoin,*1/*1,CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",CPIC Guideline Annotation,PA450947,,,,,,,
CYP2C9,piroxicam,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA450985,,,,,,,
CYP2C9,siponimod,*1/*1,The guideline does not provide a description of the impact of a normal metabolizer phenotype on siponimod.,The guideline does not provide a recommendation for siponimod in normal metabolizers.,DPWG Guideline Annotation,PA166182736,,,,,,,
CYP2C9,tenoxicam,*1/*1,CYP2C9: Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",CPIC Guideline Annotation,PA131890625,,,,,,,
CYP2C9,warfarin,*1/*1,,The guideline does not provide a recommendation for warfarin in normal metabolizers.,CPIC Guideline Annotation,PA451906,,,,,,,
CYP2D6,amitriptyline,*1/*3,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA448385,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,amoxapine,*1/*3,,&quot;May alter systemic concentrations.&quot;,FDA PGx Association,PA448405,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,aripiprazole,*1/*3,The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.,NO action is needed for this gene-drug interaction.,DPWG Guideline Annotation,PA10026,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,atomoxetine,*1/*3,CYP2D6: Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.,"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.
<h4 id=""other-considerations"">Other Considerations</h4>
Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",CPIC Guideline Annotation,PA134688071,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,brexpiprazole,*1/*3,"There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation.",NO action is required for this gene-drug interaction.,DPWG Guideline Annotation,PA166160053,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,clomipramine,*1/*3,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449048,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,codeine,*1/*3,CYP2D6: Reduced morphine formation,"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",CPIC Guideline Annotation,PA449088,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,desipramine,*1/*3,CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.,"Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449233,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,doxepin,*1/*3,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449409,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,eliglustat,*1/*3,"This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.","Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:
<ul>
<li>Eliglustat is contra-indicated. Choose an alternative if possible.</li>
</ul>
<em>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</em>
Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):
<ul>
<li>Use a dose of 84mg eliglustat 1x daily.</li>
</ul>
Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):
<ul>
<li>Consider a dose of 84mg eliglustat 1x daily. Be alert to side effects.</li>
</ul>
Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):
<ul>
<li>Choose an alternative if possible.</li>
<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>
</ul>
Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):
<ul>
<li>Choose an alternative.</li>
<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>
</ul>
Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.
<ul>
<li>Choose an alternative if possible.</li>
</ul>
NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:
<ul>
<li>Use the standard dose of 84mg 2x daily.</li>
</ul>",DPWG Guideline Annotation,PA166123486,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,fluvoxamine,*1/*3,CYP2D6: Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.,Initiate therapy with recommended starting dose.,CPIC Guideline Annotation,PA449690,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,hydrocodone,*1/*3,CYP2D6: Minimal evidence for pharmacokinetic or clinical effect.,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",CPIC Guideline Annotation,PA449900,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,imipramine,*1/*3,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA449969,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,meclizine,*1/*3,"""The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.""","&quot;... when ANTIVERT® [meclizine] is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.&quot; See label for more information.",FDA Label Annotation,PA450338,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,metoprolol,*1/*3,"Decreased metabolism of metoprolol leading to increased drug concentrations; however, this does not appear to translate into clinically significant changes in heart rate, blood pressure, or clinical outcomes",Initiate standard dosing,CPIC Guideline Annotation,PA450480,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,nortriptyline,*1/*3,CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.,"Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA450657,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,ondansetron,*1/*3,CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers,"Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",CPIC Guideline Annotation,PA450705,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,paroxetine,*1/*3,"CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side
effects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.","Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",CPIC Guideline Annotation,PA450801,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,pimozide,*1/*3,"The risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The elevated plasma concentration and associated theoretical increased risk of QT elongation can be negated by following the dose recommendations provided below.","Use no more than the following doses (80% of the normal maximum dose):
<ul>
<li>12 years and older: 16 mg/day</li>
<li>younger than 12 years: 0.08 mg/kg per day to a maximum of 3 mg/day</li>
</ul>",DPWG Guideline Annotation,PA450965,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,propafenone,*1/*3,Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.,"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.
<ul>
<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects.</li>
<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>
</ul>",DPWG Guideline Annotation,PA451131,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,risperidone,*1/*3,"There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.",NO action is needed for this gene-drug interaction.,DPWG Guideline Annotation,PA451257,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,tamoxifen,*1/*3,"CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",CPIC Guideline Annotation,PA451581,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,tetrabenazine,*1/*3,,"&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of
CYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at
weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces
chorea. Doses above 50 mg per day should be given in a three times a day regimen. The
maximum recommended daily dose is 100 mg and the maximum recommended single dose is
37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or
sedation occur, titration should be stopped and the dose should be reduced. If the adverse
reaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment
or initiating other specific treatment.&quot; See label for more information",FDA Label Annotation,PA140222719,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,thioridazine,*1/*3,,"&quot;...thioridazine is contraindicated...in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.&quot; See label for more information.",FDA Label Annotation,PA451666,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,tramadol,*1/*3,CYP2D6: Reduced O-desmethyltramadol (active metabolite) formation,"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",CPIC Guideline Annotation,PA451735,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,trimipramine,*1/*3,CYP2C19: Normal metabolism of tertiary amines;CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects,"Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",CPIC Guideline Annotation,PA451791,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,tropisetron,*1/*3,CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers,"Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
<h4 id=""other-considerations"">Other Considerations</h4>
Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",CPIC Guideline Annotation,PA161925594,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,venlafaxine,*1/*3,CYP2D6: Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.,No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,CPIC Guideline Annotation,PA451866,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP2D6,vortioxetine,*1/*3,CYP2D6: Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.,Initiate therapy with recommended starting dose.,CPIC Guideline Annotation,PA166122595,test,test,"rs1065852,rs1058164,rs1135840","chr22:42129130:C>G,chr22:42126611:C>G,chr22:42130692:G>A","314.64,577.64,513.64","12,18;22,17;15,11",0.42;0.44;0.6
CYP3A5,tacrolimus,*3/*3,"CYP3A5: Higher (""normal"") dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations.","Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.
<h4 id=""other-considerations"">Other Considerations</h4>
This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",CPIC Guideline Annotation,PA451578,test,test,rs776746,chr7:99672916:T>C,1807.06,"0,52",1.0
CYP4F2,warfarin,*1/*17,,,CPIC Guideline Annotation,PA451906,test,test,rs4020346,chr19:15878920:T>C,56.64,"39,7",0.15
DPYD,capecitabine,c.1627A>G (*5) (heterozygous),"DPYD: Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity","Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",CPIC Guideline Annotation,PA448771,test,test,rs1801159,chr1:97515839:T>C,560.64,"21,18",0.46
DPYD,fluorouracil,c.1627A>G (*5) (heterozygous),"DPYD: Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity","Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",CPIC Guideline Annotation,PA128406956,test,test,rs1801159,chr1:97515839:T>C,560.64,"21,18",0.46
G6PD,dapsone,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA449211,,,,,,,
G6PD,methylene blue,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA450457,,,,,,,
G6PD,nitrofurantoin,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA450640,,,,,,,
G6PD,pegloticase,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA165963961,,,,,,,
G6PD,primaquine,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA451103,,,,,,,
G6PD,rasburicase,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,No reason to avoid based on G6PD status,CPIC Guideline Annotation,PA10176,,,,,,,
G6PD,tafenoquine,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,"No reason to avoid based on G6PD status
<h4 id=""other-considerations"">Other Considerations</h4>
Tafenoquine’s safety has been established for a G6PD enzyme activity ≥70% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity ≥70%.)",CPIC Guideline Annotation,PA166115580,,,,,,,
G6PD,toluidine blue,B (reference)/B (reference),G6PD: Low risk of acute hemolytic anemia,"No reason to avoid based on G6PD status
<h4 id=""other-considerations"">Other Considerations</h4>
Toluidine blue classification strength is based on extrapolation from methylene blue data",CPIC Guideline Annotation,PA166268821,,,,,,,
HLA-A,carbamazepine,*31:01/*31:01,"HLA-A: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE;HLA-B: Greater risk of carbamazepine-induced SJS/TEN","If patient is carbamazepine-naïve, do not use carbamazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",CPIC Guideline Annotation,PA448785,,,,,,,
HLA-B,abacavir,*15:02/*57:01,HLA-B: Significantly increased risk of abacavir hypersensitivity,Abacavir is not recommended,CPIC Guideline Annotation,PA448004,,,,,,,
HLA-B,allopurinol,*15:02/*57:01,HLA-B: Low or reduced risk of allopurinol-induced SCAR,Use allopurinol per standard dosing guidelines,CPIC Guideline Annotation,PA448320,,,,,,,
HLA-B,carbamazepine,*15:02/*57:01,"HLA-A: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE;HLA-B: Greater risk of carbamazepine-induced SJS/TEN","If patient is carbamazepine-naïve, do not use carbamazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",CPIC Guideline Annotation,PA448785,,,,,,,
HLA-B,fosphenytoin,*15:02/*57:01,CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",CPIC Guideline Annotation,PA164746820,,,,,,,
HLA-B,oxcarbazepine,*15:02/*57:01,HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN,"If patient is oxcarbazepine-naïve, do not use oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",CPIC Guideline Annotation,PA450732,,,,,,,
HLA-B,pazopanib,*15:02/*57:01,,&quot;May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.&quot;,FDA PGx Association,PA165291492,,,,,,,
HLA-B,phenytoin,*15:02/*57:01,CYP2C9: Normal phenytoin metabolism;HLA-B: Increased risk of phenytoin-induced SJS/TEN,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
<h4 id=""other-considerations"">Other Considerations</h4>
Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",CPIC Guideline Annotation,PA450947,,,,,,,
NUDT15,azathioprine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA448515,,,,,,,
NUDT15,mercaptopurine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA450379,,,,,,,
NUDT15,thioguanine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA451663,,,,,,,
RYR1,desflurane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA164749136,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,enflurane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA449461,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,halothane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA449845,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,isoflurane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA450106,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,methoxyflurane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA450434,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,sevoflurane,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA451341,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
RYR1,succinylcholine,c.11266C>G (heterozygous),"These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",CPIC Guideline Annotation,PA451522,test,test,rs4802584,chr19:38534726:C>G,839.64,"18,25",0.58
SLCO1B1,atorvastatin,*15/*15,SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.,"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA448500,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,elagolix,*15/*15,,&quot;Results in higher systemic concentrations.&quot;,FDA PGx Association,PA166182348,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,fluvastatin,*15/*15,CYP2C9: Normal exposure.;SLCO1B1: Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.,"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses &gt;40mg per day.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA449688,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,lovastatin,*15/*15,SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA450272,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,pitavastatin,*15/*15,SLCO1B1: Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.,"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose &gt;1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA142650384,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,pravastatin,*15/*15,SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.,"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA451089,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,rosuvastatin,*15/*15,ABCG2: Typical myopathy risk and rosuvastatin exposure;SLCO1B1: Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.,"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose &gt; 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA134308647,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
SLCO1B1,simvastatin,*15/*15,SLCO1B1: Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
<h4 id=""other-considerations"">Other Considerations</h4>
The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",CPIC Guideline Annotation,PA451363,test,test,"rs2306283,rs4149056","chr12:21176804:A>G,chr12:21178615:T>C","1536.06,1829.06","0,55;0,47",1.0
TPMT,azathioprine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA448515,,,,,,,
TPMT,mercaptopurine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA450379,,,,,,,
TPMT,thioguanine,*1/*1,"NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression;TPMT: Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.","Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).
<h4 id=""other-considerations"">Other Considerations</h4>
Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",CPIC Guideline Annotation,PA451663,,,,,,,
UGT1A1,atazanavir,*1/*1,UGT1A1: Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.,"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).
<h4 id=""other-considerations"">Other Considerations</h4>
All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat. &quot;reference&quot; function refers to the UGT1A1 allele to which other alleles are compared.",CPIC Guideline Annotation,PA10251,,,,,,,
UGT1A1,irinotecan,*1/*1,The guideline does not provide a description of the impact of a normal metabolizer phenotype on irinotecan.,The guideline does not provide a recommendation for irinotecan in normal metabolizers,DPWG Guideline Annotation,PA450085,,,,,,,
VKORC1,warfarin,rs9923231 variant (T)/rs9923231 variant (T),,"Use 60% of the standard initial dose.
The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see
https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica.
From day 6 on the standard algorithm without genotype information can be used to calculate the dose.",CPIC Guideline Annotation,PA451906,test,test,rs9923231,chr16:31096368:C>T,1626.06,"0,42",1.0
